MCID: RFR002
MIFTS: 35

Refractory Hairy Cell Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Refractory Hairy Cell Leukemia

MalaCards integrated aliases for Refractory Hairy Cell Leukemia:

Name: Refractory Hairy Cell Leukemia 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:711
NCIt 50 C8030
UMLS 73 C0279780

Summaries for Refractory Hairy Cell Leukemia

Disease Ontology : 12 A refractory hematologic cancer that is a mature B cell cancer that does not yield readily to treatment.

MalaCards based summary : Refractory Hairy Cell Leukemia is related to hairy cell leukemia and leukemia. An important gene associated with Refractory Hairy Cell Leukemia is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and MAP Kinase Signaling. The drugs Cefepime and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are Decreased viability in esophageal squamous lineage and Reduced mammosphere formation

Related Diseases for Refractory Hairy Cell Leukemia

Diseases related to Refractory Hairy Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)
# Related Disease Score Top Affiliating Genes
1 hairy cell leukemia 30.9 BRAF CD22
2 leukemia 10.5
3 cardiofaciocutaneous syndrome 1 10.0 BRAF MAP2K7
4 aspergillosis 9.8
5 hematopoietic stem cell transplantation 9.8
6 noonan syndrome 1 9.8 BRAF MAP2K7
7 pancreas adenocarcinoma 9.6 MAP2K7 MSLN
8 skin melanoma 9.5 BRAF MAP2K7
9 hematologic cancer 9.1 CD22 CDA CSF3
10 leukemia, acute myeloid 9.0 CD22 CSF3 MAP2K7
11 lymphoma, non-hodgkin, familial 8.7 BRAF CD22 CD52 CSF3
12 refractory hematologic cancer 7.2 CD22 CD52 CDA CSF3 MAP2K7 MSLN

Graphical network of the top 20 diseases related to Refractory Hairy Cell Leukemia:



Diseases related to Refractory Hairy Cell Leukemia

Symptoms & Phenotypes for Refractory Hairy Cell Leukemia

GenomeRNAi Phenotypes related to Refractory Hairy Cell Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.35 BRAF CD22 CD52 CDA CSF3
2 Reduced mammosphere formation GR00396-S 8.92 BRAF CD22 CD52 CSF3

Drugs & Therapeutics for Refractory Hairy Cell Leukemia

Drugs for Refractory Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 303)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
2
Ofloxacin Approved Phase 3 82419-36-1 4583
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
5
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
6
Tazobactam Approved Phase 3 89786-04-9 123630
7
Ribavirin Approved Phase 3 36791-04-5 37542
8
Captopril Approved Phase 3 62571-86-2 44093
9
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
10
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
11
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
12
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
15
Piperacillin Approved Phase 3 66258-76-2 43672
16
Vancomycin Approved Phase 3 1404-90-6 441141 14969
17
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
18
Acyclovir Approved Phase 3 59277-89-3 2022
19
Ondansetron Approved Phase 3,Phase 2,Not Applicable 99614-02-5 4595
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
22
Dalteparin Approved Phase 3 9005-49-6
23
Palivizumab Approved, Investigational Phase 3 188039-54-5
24
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
25
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
26
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
27
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
28 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Not Applicable 979-32-8
29
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
30
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
31
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
32
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
33
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
34
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
35 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
36 Analgesics Phase 3,Not Applicable
37 Alkylating Agents Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
38 Renal Agents Phase 3,Phase 1,Phase 2
39 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable
40 Cephalosporins Phase 3
41 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
42 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Not Applicable
43 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
44 Anesthetics Phase 3
45 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
46 Anesthetics, Dissociative Phase 3
47 Anesthetics, General Phase 3
48 Anesthetics, Intravenous Phase 3
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
4 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
5 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
6 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
7 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
10 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
11 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
12 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
13 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
14 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
15 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
16 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
17 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
18 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
19 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
20 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
21 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia Active, not recruiting NCT01829711 Phase 3 moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
22 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
23 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
24 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
25 Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy Completed NCT00003757 Phase 2
26 BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia Completed NCT00074048 Phase 2 BL22
27 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
28 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
29 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
30 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
31 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
32 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
33 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
35 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
36 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
37 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
38 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
39 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
40 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
41 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
42 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
43 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
44 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
45 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
46 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
47 Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00002673 Phase 2
48 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
49 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
50 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide

Search NIH Clinical Center for Refractory Hairy Cell Leukemia

Genetic Tests for Refractory Hairy Cell Leukemia

Anatomical Context for Refractory Hairy Cell Leukemia

MalaCards organs/tissues related to Refractory Hairy Cell Leukemia:

41
Bone, Bone Marrow, B Cells, T Cells, Liver, Kidney, Colon

Publications for Refractory Hairy Cell Leukemia

Articles related to Refractory Hairy Cell Leukemia:

(show all 21)
# Title Authors Year
1
MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab. ( 29285581 )
2017
2
Ibrutinib for relapsed refractory hairy cell leukemia variant. ( 27733095 )
2016
3
Refractory hairy cell leukemia-variant. ( 27727469 )
2016
4
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. ( 26352686 )
2015
5
Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. ( 24863690 )
2014
6
Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt. ( 24789721 )
2014
7
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. ( 23690412 )
2013
8
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. ( 24097860 )
2013
9
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. ( 24337488 )
2013
10
Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. ( 22223825 )
2012
11
Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia. ( 22165992 )
2012
12
BRAF inhibition in refractory hairy-cell leukemia. ( 22621641 )
2012
13
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. ( 21599609 )
2011
14
Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation. ( 19330554 )
2009
15
Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. ( 18259114 )
2008
16
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. ( 17886250 )
2007
17
Immunotoxins in the treatment of refractory hairy cell leukemia. ( 16990113 )
2006
18
Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. ( 15646655 )
2004
19
Rituximab in relapsed or refractory hairy cell leukemia. ( 12816862 )
2003
20
Responses in refractory hairy cell leukemia to a recombinant immunotoxin. ( 10552943 )
1999
21
Fludarabine phosphate in refractory hairy cell leukemia. ( 1708945 )
1991

Variations for Refractory Hairy Cell Leukemia

Expression for Refractory Hairy Cell Leukemia

Search GEO for disease gene expression data for Refractory Hairy Cell Leukemia.

Pathways for Refractory Hairy Cell Leukemia

Pathways related to Refractory Hairy Cell Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.32 CD22 CSF3
2 11.21 BRAF MAP2K7
3
Show member pathways
10.95 CD52 MSLN
4 10.61 CD22 CSF3

GO Terms for Refractory Hairy Cell Leukemia

Biological processes related to Refractory Hairy Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-serine phosphorylation GO:0033138 8.96 BRAF CSF3
2 C-terminal protein lipidation GO:0006501 8.62 CD52 MSLN

Sources for Refractory Hairy Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....